Table 1 Summary of the published studies investigating the effect of therapeutic plasma exchange for COVID-19
Trials | Study design | Sample size (TPE/control) | TPE replacement fluids | Number of TPE treatment | Results (mortality rate, MV, LOS) |
|---|---|---|---|---|---|
Gucyetmez et al. [13] | Retrospective study with PSM | 12/12 | Not mentioned | Not mentioned | ・ Mortality rate—mortality, 8% vs. 58%, p < 0.01 ・ MV—duration of MV, 316 h vs. 278 h, p = 0.67 ・LOS—ICU LOS, 20 days vs. 14 days, p = 0.07 |
Kamran et al. [14] | Retrospective study with PSM | 45/45 | FFP: normal saline = 2:1 | Daily until recovery | ・Mortality rate—overall survival, 91% vs. 62%, p < 0.01 ・ LOS—Total LOS, 10 days vs. 15 days, p = 0.01 |
Khamis et al. [15] | Retrospective study | 11/20 | FFP | 5 times | ・ Mortality rate—all-cause mortality, 9% vs. 45%, p = 0.055 28 day mortality, 0% vs. 35%, p = 0.033 14 day mortality, 0% vs. 35%, p = 0.033 ・ MV—extubation, 73% vs. 20%, p = 0.02 ・ LOS—total LOS, 19 days vs. 11 days, p = 0.13 ICU LOS, 14 days vs. 6 days, p = 0.03 |
Faqihi et al. [16] | RCT | 34/39 | FFP or artificial Ocyaplas LG® | Maximum of 5 times | ・ Mortality rate—35 day mortality, 21% vs. 34%, p = 0.09 ・ MV—duration of MV, 15 days vs. 19 days, p < 0.01 ・ LOS—ICU LOS, 19 days vs. 26 days, p = 0.02 |